InnFocus MicroShunt Versus Trabeculectomy Study
Status: | Active, not recruiting |
---|---|
Conditions: | Ocular |
Therapuetic Areas: | Ophthalmology |
Healthy: | No |
Age Range: | 40 - 85 |
Updated: | 8/5/2018 |
Start Date: | August 2013 |
End Date: | November 2019 |
A Randomized Study Comparing the Safety and Efficacy of the InnFocus MicroShuntTM Glaucoma Drainage System to Standard Trabeculectomy In Subjects With Primary Open Angle Glaucoma
Assess the safety and effectiveness of the InnFocus MicroShunt when used to lower intraocular
pressure (IOP) in subjects with primary open angle glaucoma where the IOP is not controlled
when using maximum tolerated glaucoma medications.
pressure (IOP) in subjects with primary open angle glaucoma where the IOP is not controlled
when using maximum tolerated glaucoma medications.
This clinical trial is a prospective, randomized, controlled, multicenter, study. After
informed consent is obtained, patients will be evaluated for eligibility based on glaucoma
severity, eye health, and visual acuity.
Clinical follow up will be scheduled over the course of the 24 month study, and examinations
will be repeated to monitor eye health. At the 1 and 2 year follow up, diurnal (IOP taken in
the morning, mid-day, and afternoon in the same day) IOP evaluation will be done. Annual
follow up will occur up to 2 years. The primary effectiveness endpoint is 20% or greater
reduction in IOP from pre-op medicated IOP at 12 months.
informed consent is obtained, patients will be evaluated for eligibility based on glaucoma
severity, eye health, and visual acuity.
Clinical follow up will be scheduled over the course of the 24 month study, and examinations
will be repeated to monitor eye health. At the 1 and 2 year follow up, diurnal (IOP taken in
the morning, mid-day, and afternoon in the same day) IOP evaluation will be done. Annual
follow up will occur up to 2 years. The primary effectiveness endpoint is 20% or greater
reduction in IOP from pre-op medicated IOP at 12 months.
Inclusion Criteria: - POAG on maximum tolerated glaucoma meds - Medicated ≥15mmHg and
≤40mmHg - Exclusion Criteria: - Previous conjunctival incisional ophthalmic surgery -
Anticipated need for additional ocular surgery during the study - Secondary glaucoma - Any
condition that prevents the device implantation or trabeculectomy in the superior region of
the study eye
We found this trial at
25
sites
Bellevue, Washington 98004
Principal Investigator: Howard Barneby, MD
Phone: 425-454-3937
Click here to add this to my saved trials
100 Presidential Boulevard
Bala-Cynwyd, Pennsylvania 19004
Bala-Cynwyd, Pennsylvania 19004
Principal Investigator: Marlene Moster, M.D.
Phone: 484-434-2706
Click here to add this to my saved trials
Bloomington, Minnesota 55431
Principal Investigator: Christine Larsen, M.D.
Click here to add this to my saved trials
Chevy Chase, Maryland
Principal Investigator: Kenneth Schwartz, M.D.
Phone: 301-654-5114
Click here to add this to my saved trials
Cincinnati, Ohio 45242
Principal Investigator: Anup Khatana, M.D.
Phone: 513-569-3682
Click here to add this to my saved trials
Columbus, Ohio 43215
Principal Investigator: Doug Baker, M.D.
Click here to add this to my saved trials
Dallas, Texas 75231
Principal Investigator: Davinder Grover, M.D.
Phone: 214-765-9720
Click here to add this to my saved trials
Davis, California 95817
Principal Investigator: Michelle Lim, M.D.
Click here to add this to my saved trials
Eagle, Idaho 83616
Principal Investigator: Adam Reynolds, M.D.
Phone: 208-841-8624
Click here to add this to my saved trials
Fairfield, Connecticut 06824
Principal Investigator: Robert Noecker, MD
Phone: 203-237-1818
Click here to add this to my saved trials
Fayetteville, Arkansas 72704
Principal Investigator: Steven Vold, MD
Phone: 479-442-8653
Click here to add this to my saved trials
Click here to add this to my saved trials
Glendale, Arizona 85306
Principal Investigator: George Reiss, M.D.
Click here to add this to my saved trials
Glenview, Illinois 60026
Principal Investigator: Steven Brown, M.D.
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Robert Feldman, M.D.
Phone: 713-559-5200
Click here to add this to my saved trials
Indianapolis, Indiana 46290
Principal Investigator: Louis Cantor, M.D.
Phone: 317-814-2745
Click here to add this to my saved trials
Los Angeles, California 90095
Principal Investigator: Joseph Caprioli, M.D.
Click here to add this to my saved trials
New York, New York 10003
Principal Investigator: Joseph Panarelli, M.D.
Click here to add this to my saved trials
Oklahoma City, Oklahoma 73104
Principal Investigator: Mahmoud Khaimi, M.D.
Phone: 405-271-6307
Click here to add this to my saved trials
Click here to add this to my saved trials
Overland Park, Kansas 66213
Principal Investigator: Michael Stiles, MD
Phone: 913-681-1601
Click here to add this to my saved trials
46 Avenue du Docteur Albert Schweitzer
Pessac, Bordeaux 33600
Pessac, Bordeaux 33600
Principal Investigator: Isabelle Riss, MD
Phone: 33-6-185-42-752
Click here to add this to my saved trials
San Antonio, Texas 78229
Principal Investigator: William Flynn, M.D.
Click here to add this to my saved trials
Slingerlands, New York 12159
Principal Investigator: Steven Simmons, M.D.
Phone: 518-475-7300
Click here to add this to my saved trials
Tucson, Arizona 85710
Principal Investigator: Jason Levine, M.D.
Phone: 520-327-3487
Click here to add this to my saved trials